- Home
- ULH vs NMRA Comparison
ULH vs NMRA Comparison
Compare ULH & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ULH | NMRA |
|---|---|---|
| Founded | 1932 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.1M | 424.4M |
| IPO Year | 2005 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ULH | NMRA |
|---|---|---|
| Price | $15.72 | $2.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $17.00 | $8.00 |
| AVG Volume (30 Days) | 41.4K | ★ 2.4M |
| Earning Date | 02-06-2026 | 03-02-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,638,101,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.78 | $0.61 |
| 52 Week High | $47.42 | $3.25 |
Technical Indicators
Market Signals| Indicator | ULH | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 50.00 |
| Support Level | $15.27 | $2.00 |
| Resistance Level | $18.30 | $2.20 |
| Average True Range (ATR) | 1.05 | 0.16 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 15.60 | 27.40 |
Price Performance
Historical ComparisonAbout ULH Universal Logistics Holdings Inc.
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.